V170
Biological
Merck Sharp & Dohme Corporation
Total Payments
$169,677
Transactions
3
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $169,677 | 3 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $169,677 | 3 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| RSV Incidence and Hospitalization Associated Disability in Adults | Merck Sharp & Dohme Corporation | $169,677 | 0 |
Top Doctors Receiving Payments for V170
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New York, NY | $169,677 | 3 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $169,677
Product Information
- Type Biological
- Total Payments $169,677
- Total Doctors 0
- Transactions 3
About V170
V170 is a biological associated with $169,677 in payments to 0 healthcare providers, recorded across 3 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2017. In 2017, $169,677 was paid across 3 transactions to 0 doctors.
The most common payment nature for V170 is "Unspecified" ($169,677, 100.0% of total).
V170 is associated with 1 research study, including "RSV Incidence and Hospitalization Associated Disability in Adults" ($169,677).